Abstract: A method for updating an operating system (OS) and a handheld electronic apparatus are provided. In the method, when an updating instruction is received by the handheld electronic apparatus, an updating procedure is executed by an updating module of firmware in the handheld electronic apparatus. The updating procedure includes steps of backing up item data in a first storage area to a second storage area, updating the OS that is installed on the first storage area, and restoring the item data from the second storage area to the first storage area after the OS is completely updated.

Abstract: A mounting apparatus for a data storage device includes a bracket, a plurality of shock absorbers positioned between the data storage device and the bracket, a plurality of fasteners, and two elastic members. The bracket includes a bottom plate, and two sidewalls. Each of the plurality of shock absorbers includes a shock absorber pad, and a bushing protruding from an outer side of the shock absorber pad. The shock absorber pad defines a first through hole therein. Each of the plurality of fasteners includes a post and a head portion. The post is passed through the bushing, the first through hole of the shock absorber pad to engage one of a plurality of second mounting holes of the data storage device. Each of the two elastic members is fixed to the inner side of one of the two sidewalls of the bracket.

Abstract: The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme. Specifically, the invention is directed to (Cis)-N-{[4-cyano-2-(trifluoromethyl)phenyl]methyl}-3-{[4-methyl-6-(methylamino)-1,3,5-triazin-2-yl]amino}cyclohexanecarboxamide; or a pharmaceutically acceptable salt thereof, and N-{[4-cyano-2-(trifluoromethyl)phenyl]methyl}-3-{[4-methyl-6-(methylamino)-1,3,5-triazin-2-yl]amino}cyclohexanecarboxamide; or a pharmaceutically acceptable salt thereof.

Abstract: The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme. Specifically, the invention is directed to compounds according to Formula I: wherein R1, R2, R4, R5, R6, A, B, Y, Z, n, and m are defined below, and to pharmaceutically-acceptable salts thereof. The compounds of the invention are sEH inhibitors and can be used in the treatment of diseases mediated by the sEH enzyme, such as hypertension. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting sEH and treatment of conditions associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Abstract: A mounting apparatus for a data storage device includes a bracket, a plurality of shock absorbers positioned between the data storage device and the bracket, a plurality of fasteners, and two elastic members. The bracket includes a bottom plate, and two sidewalls. Each of the plurality of shock absorbers includes a shock absorber pad, and a bushing protruding from an outer side of the shock absorber pad. The shock absorber pad defines a first through hole therein. Each of the plurality of fasteners includes a post and a head portion. The post is passed through the bushing, the first through hole of the shock absorber pad to engage one of a plurality of second mounting holes of the data storage device. Each of the two elastic members is fixed to the inner side of one of the two sidewalls of the bracket.

Abstract: The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme. Specifically, the invention is directed to compounds according to Formula I: wherein R1, R2, R3, R5a, R6a A, B, Y, x, and m are defined below, and to pharmaceutically-acceptable salts thereof. The compounds of the invention are sEH inhibitors and can be used in the treatment of diseases mediated by the sEH enzyme, such as hypertension. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting sEH and treatment of conditions associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Abstract: The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme.

Abstract: A semi-submersible structure. The hull includes four columns that are supported by two pontoons. The columns support the topsides and the topsides structural framing serves as horizontal framing between the columns. A truss frame is attached to the columns. The truss frame preferably includes heave plates. The truss frame extends downward below the pontoons a sufficient distance in the water such that it minimizes motions caused by environmental forces. The hull section and the truss space frame are constructed separately and assembled together at the offshore site where the structure is used for drilling and/or production.

Abstract: A method of mating of a buoyant hull with a truss structure while at the installation site of the completed offshore structure. The buoyant hull is moored in place. The truss structure is placed in the water, self upends, and maneuvered near the buoyant hull. The buoyant hull and truss structure are rigged with lines to allow the truss structure to be pulled into engagement with the buoyant hull. The truss structure is lowered to a predetermined depth below the water surface but above the sea floor and the weight is transferred to the lines from the buoyant hull. The truss structure is aligned with the buoyant hull and lines from the buoyant hull are used to pull the truss structure into engagement with the buoyant hull. The truss structure and buoyant hull are rigidly attached together as is customary using grouting and welding.

Abstract: A method of mating of a buoyant hull with a truss structure while at the installation site of the completed offshore structure. The buoyant hull is moored in place. The truss structure is placed in the water, self upends, and maneuvered near the buoyant hull. The buoyant hull and truss structure are rigged with lines to allow the truss structure to be pulled into engagement with the buoyant hull. The truss structure is lowered to a predetermined depth below the water surface but above the sea floor and the weight is transferred to the lines from the buoyant hull. The truss structure is aligned with the buoyant hull and lines from the buoyant hull are used to pull the truss structure into engagement with the buoyant hull. The truss structure and buoyant hull are rigidly attached together as is customary using grouting and welding.

Abstract: A floating offshore structure having a buoyant hull with an open truss frame having heave plates vertically spaced along the truss frame. One or more of the heave plates include a skirt plate that is attached around the outer perimeter of the heave plate and increases the effectiveness of the heave plate at trapping water mass between the heave plates for reducing heave motions of the floating offshore structure. A skirt plate is attached to one or more heave plates at essentially a right angle to the heave plate. The skirt plate may extend beyond the upper and lower surfaces of the heave plate or be positioned so as to be flush with the one surface of the heave plate and extend only beyond the opposite surface of the heave plate.

Abstract: The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme. Specifically, the invention is directed to (Cis)-N-{[4-cyano-2-(trifluoromethyl)phenyl]methyl}-3-{[4-methyl-6-(methylamino)-1,3,5-triazin-2-yl]amino}cyclohexanecarboxamide; or a pharmaceutically acceptable salt thereof, and N-{[4-cyano-2-(trifluoromethyl)phenyl]methyl}-3-{[4-methyl-6-(methylamino)-1,3,5-triazin-2-yl]amino}cyclohexanecarboxamide; or a pharmaceutically acceptable salt thereof. The compounds of the invention can be used in the treatment of diseases mediated by the sEH enzyme, such as hypertension, asthma, and COPD. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting sEH and treatment of conditions associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Abstract: The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme. Specifically, the invention is directed to compounds according to Formula I: wherein R1, R2, R5a, R6a, A, B, Y, I, and m are defined below, and to pharmaceutically-acceptable salts thereof. The compounds of the invention are sEH inhibitors and can be used in the treatment of diseases mediated by the sEH enzyme, such as hypertension. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting sEH and treatment of conditions associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Abstract: The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme. Specifically, the invention is directed to compounds according to Formula I: wherein R1, R2, R4, R5, R6, A, B, Y, Z, n, and m are defined below, and to pharmaceutically-acceptable salts thereof. The compounds of the invention are sEH inhibitors and can be used in the treatment of diseases mediated by the sEH enzyme, such as hypertension. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting sEH and treatment of conditions associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Abstract: The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme. Specifically, the invention is directed to compounds according to Formula I: wherein R1, R2, R3, R5a, R6a A, B, Y, x, and m are defined below, and to pharmaceutically-acceptable salts thereof. The compounds of the invention are sEH inhibitors and can be used in the treatment of diseases mediated by the sEH enzyme, such as hypertension. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting sEH and treatment of conditions associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Abstract: The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme.

Abstract: A semi-submersible structure. The hull includes four columns that are supported by two pontoons. The columns support the topsides and the topsides structural framing serves as horizontal framing between the columns. A truss frame is attached to the columns. The truss frame preferably includes heave plates. The truss frame extends downward below the pontoons a sufficient distance in the water such that it minimizes motions caused by environmental forces. The hull section and the truss space frame are constructed separately and assembled together at the offshore site where the structure is used for drilling and/or production.

Abstract: A semi-submersible structure. The hull includes four columns that are supported by two pontoons. The columns support the topsides and the topsides structural framing serves as horizontal framing between the columns. A truss frame is attached to the columns. The truss frame preferably includes heave plates. The truss frame extends downward below the pontoons a sufficient distance in the water such that it minimizes motions caused by environmental forces. The hull section and the truss space frame are constructed separately and assembled together at the offshore site where the structure is used for drilling and/or production.